Table 1.
Clinical characteristics of study populations
| Discovery stage, N (%) |
Internal validation, N (%) |
External validation, N (%) |
||||
|---|---|---|---|---|---|---|
| HPV(+) | HPV(−) | HPV(+) | HPV(−) | HPV(+) | HPV(−) | |
| N | 5 (50.0) | 5 (50.0) | 15 (53.6) | 13 (46.4) | 79 (50.3) | 78 (49.7) |
| Age (years) | ||||||
| Mean (SD) | 58 (6.6) | 58.8 (5.2) | 58.1 (10.6) | 61.6 (10.6) | 55 (8.6) | 58 (10.12) |
| Median (range) | 55 (51–66) | 58 (52–64) | 54 (46–83) | 59 (48–83) | 56 (39–78) | 58 (42–86) |
| Gender | ||||||
| Female | 1 (20.0) | 1 (20.0) | 0 | 7 (53.8) | 12 (15.2) | 14 (20.6) |
| Male | 4 (80.0) | 4 (80.0) | 15 (100.0) | 6 (46.2) | 67 (84.8) | 64 (79.4) |
| Smoking status | ||||||
| Never | 0 | 0 | 5 (33.3) | 0 | 24 (30.8) | 23 (30.6) |
| Former | 3 (60.0) | 3 (60.0) | 5 (33.3) | 4 (30.8) | 50 (64.1) | 35 (46.7) |
| Current | 2 (40.0) | 2 (40.0) | 5 (33.3) | 9 (69.2) | 4 (5.1) | 17 (22.7) |